0 citations0 references

Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer

bioRxiv (Cold Spring Harbor Laboratory)2019

Citations Over Time

Stephan B. Dreyer, Rosanna Upstill‐Goddard, Viola Paulus-Hock, Clara Paris, Eirini-Maria Lampraki, Eloïse Dray, Bryan Serrels, Giuseppina Caligiuri, Selma Rebus, Holly Brunton, Richard Cunningham, Craig Nourse, Ulla‐Maja Bailey, Marc D. Jones, Kim Moran‐Jones, Derek Wright, Fraser R. Duthie, Karin Oien, Lisa Evers, Colin J. McKay, Grant A. McGregor, Aditi Gulati, Rachel Brough, Ilirjana Bajrami, Stephan Pettitt, Michele Dziubinski, Juliana Candido, Frances R. Balkwill, Simon T. Barry, Robert Grützmann, Lola Rahib, Australian Pancreatic Cancer Genome Initiative, Amber L. Johns, Marina Pajic, Fieke E. M. Froeling, Philip Beer, Elizabeth A. Musgrove, Gloria M. Petersen, Alan Ashworth, Margaret C. Frame, Howard C. Crawford, Diane M. Simeone, Christopher J. Lord, Debabrata Mukhopadhyay, Christian Pilarsky, Susanna L. Cooke, Nigel B. Jamieson, Jennifer P. Morton, Owen J. Sansom, Peter J. Bailey, Andrew V. Biankin, David K. Chang

Abstract

ABSTRACT Continuing recalcitrance to therapy cements pancreatic cancer (PC) as the most lethal malignancy, which is set to become the second leading cause of cancer death in our society. We interrogated the transcriptome, genome, proteome and functional characteristics of 61 novel PC patient-derived cell lines to define novel therapeutic strategies targeting the DNA damage response (DDR) and replication stress. We show that patient-derived cell lines faithfully recapitulate the epithelial component of pancreatic tumors including previously described molecular subtypes. Biomarkers of DDR deficiency, including a novel signature of homologous recombination deficiency, co-segregates with response to platinum and PARP inhibitor therapy in vitro and in vivo . We generated a novel signature of replication stress with potential clinical utility in predicting response to ATR and WEE1 inhibitor treatment. Replication stress and DDR deficiency are independent of each other, creating opportunities for therapy in DDR proficient PC, and post-platinum therapy. Abstract Figure STATEMENT OF SIGNIFICANCE We define therapeutic strategies that target subgroups of PC using novel signatures of DNA damage response deficiency and replication stress. This potentially offers patients with DNA repair defects therapeutic options outside standard of care platinum chemotherapy and is being tested in clinical trials on the Precision-Panc platform.

Citations Over Time

Abstract

Related Papers